Stemming heart failure with cardiac- or reprogrammed-stem cells

Stem Cells Review Series

Kento Tateishi, Naofumi Takehara, Hiroaki Matsubara, Hidemasa Oh

Research output: Contribution to journalArticle

25 Citations (Scopus)

Abstract

Despite extensive efforts to control myocyte growth by genetic targeting of the cell cycle machinery and small molecules for cardiac repair, adult myocytes themselves appeared to divide a limited number of times in response to a variety of cardiac muscle stresses. Rare tissue-resident stem cells are thought to exist in many adult organs that are capable of self-renewal and differentiation and possess a range of actions that are potentially therapeutic. Recent studies suggest that a population of cardiac stem cells (CSCs) is maintained after cardiac development in the adult heart in mammals including human beings; however, homeostatic cardiomyocyte replacement might be stem cell-dependent, and functional myocardial regeneration after cardiac muscle damage is not yet considered as sufficient to fully maintain or reconstitute the cardiovascular system and function. Although it is clear that adult CSCs have limitations in their capabilities to proliferate extensively and differentiate in response to injury in vivo for replenishing mature car-diomyocytes and potentially function as resident stem cells. Transplantation of CSCs expanded ex vivo seems to require an integrated strategy of cell growth-enhancing factor(s) and tissue engineering technologies to support the donor cell survival and subsequent proliferation and differentiation in the host microenvironment. There has been substantial interest regarding the evidence that mammalian fibroblasts can be genetically reprogrammed to induced pluripotent stem (iPS) cells, which closely resemble embryonic stem (ES) cell properties capable of differentiating into functional cardiomyocytes, and these cells may provide an alternative cell source for generating patient-specific CSCs for therapeutic applications.

Original languageEnglish
Pages (from-to)2217-2232
Number of pages16
JournalJournal of Cellular and Molecular Medicine
Volume12
Issue number6A
DOIs
Publication statusPublished - Dec 2008
Externally publishedYes

Fingerprint

Stem Cells
Heart Failure
Cardiac Myocytes
Muscle Cells
Myocardium
Induced Pluripotent Stem Cells
Adult Stem Cells
Stem Cell Transplantation
Tissue Engineering
Embryonic Stem Cells
Cardiovascular System
Regeneration
Mammals
Cell Survival
Intercellular Signaling Peptides and Proteins
Cell Cycle
Fibroblasts
Tissue Donors
Technology
Wounds and Injuries

Keywords

  • Cardiac stem cells
  • Development
  • Heart failure
  • Reprogramming

ASJC Scopus subject areas

  • Cell Biology
  • Molecular Medicine

Cite this

Stemming heart failure with cardiac- or reprogrammed-stem cells : Stem Cells Review Series. / Tateishi, Kento; Takehara, Naofumi; Matsubara, Hiroaki; Oh, Hidemasa.

In: Journal of Cellular and Molecular Medicine, Vol. 12, No. 6A, 12.2008, p. 2217-2232.

Research output: Contribution to journalArticle

Tateishi, Kento ; Takehara, Naofumi ; Matsubara, Hiroaki ; Oh, Hidemasa. / Stemming heart failure with cardiac- or reprogrammed-stem cells : Stem Cells Review Series. In: Journal of Cellular and Molecular Medicine. 2008 ; Vol. 12, No. 6A. pp. 2217-2232.
@article{8f2591e704034787a85911d7d74910f5,
title = "Stemming heart failure with cardiac- or reprogrammed-stem cells: Stem Cells Review Series",
abstract = "Despite extensive efforts to control myocyte growth by genetic targeting of the cell cycle machinery and small molecules for cardiac repair, adult myocytes themselves appeared to divide a limited number of times in response to a variety of cardiac muscle stresses. Rare tissue-resident stem cells are thought to exist in many adult organs that are capable of self-renewal and differentiation and possess a range of actions that are potentially therapeutic. Recent studies suggest that a population of cardiac stem cells (CSCs) is maintained after cardiac development in the adult heart in mammals including human beings; however, homeostatic cardiomyocyte replacement might be stem cell-dependent, and functional myocardial regeneration after cardiac muscle damage is not yet considered as sufficient to fully maintain or reconstitute the cardiovascular system and function. Although it is clear that adult CSCs have limitations in their capabilities to proliferate extensively and differentiate in response to injury in vivo for replenishing mature car-diomyocytes and potentially function as resident stem cells. Transplantation of CSCs expanded ex vivo seems to require an integrated strategy of cell growth-enhancing factor(s) and tissue engineering technologies to support the donor cell survival and subsequent proliferation and differentiation in the host microenvironment. There has been substantial interest regarding the evidence that mammalian fibroblasts can be genetically reprogrammed to induced pluripotent stem (iPS) cells, which closely resemble embryonic stem (ES) cell properties capable of differentiating into functional cardiomyocytes, and these cells may provide an alternative cell source for generating patient-specific CSCs for therapeutic applications.",
keywords = "Cardiac stem cells, Development, Heart failure, Reprogramming",
author = "Kento Tateishi and Naofumi Takehara and Hiroaki Matsubara and Hidemasa Oh",
year = "2008",
month = "12",
doi = "10.1111/j.1582-4934.2008.00487.x",
language = "English",
volume = "12",
pages = "2217--2232",
journal = "Journal of Cellular and Molecular Medicine",
issn = "1582-1838",
publisher = "Wiley-Blackwell",
number = "6A",

}

TY - JOUR

T1 - Stemming heart failure with cardiac- or reprogrammed-stem cells

T2 - Stem Cells Review Series

AU - Tateishi, Kento

AU - Takehara, Naofumi

AU - Matsubara, Hiroaki

AU - Oh, Hidemasa

PY - 2008/12

Y1 - 2008/12

N2 - Despite extensive efforts to control myocyte growth by genetic targeting of the cell cycle machinery and small molecules for cardiac repair, adult myocytes themselves appeared to divide a limited number of times in response to a variety of cardiac muscle stresses. Rare tissue-resident stem cells are thought to exist in many adult organs that are capable of self-renewal and differentiation and possess a range of actions that are potentially therapeutic. Recent studies suggest that a population of cardiac stem cells (CSCs) is maintained after cardiac development in the adult heart in mammals including human beings; however, homeostatic cardiomyocyte replacement might be stem cell-dependent, and functional myocardial regeneration after cardiac muscle damage is not yet considered as sufficient to fully maintain or reconstitute the cardiovascular system and function. Although it is clear that adult CSCs have limitations in their capabilities to proliferate extensively and differentiate in response to injury in vivo for replenishing mature car-diomyocytes and potentially function as resident stem cells. Transplantation of CSCs expanded ex vivo seems to require an integrated strategy of cell growth-enhancing factor(s) and tissue engineering technologies to support the donor cell survival and subsequent proliferation and differentiation in the host microenvironment. There has been substantial interest regarding the evidence that mammalian fibroblasts can be genetically reprogrammed to induced pluripotent stem (iPS) cells, which closely resemble embryonic stem (ES) cell properties capable of differentiating into functional cardiomyocytes, and these cells may provide an alternative cell source for generating patient-specific CSCs for therapeutic applications.

AB - Despite extensive efforts to control myocyte growth by genetic targeting of the cell cycle machinery and small molecules for cardiac repair, adult myocytes themselves appeared to divide a limited number of times in response to a variety of cardiac muscle stresses. Rare tissue-resident stem cells are thought to exist in many adult organs that are capable of self-renewal and differentiation and possess a range of actions that are potentially therapeutic. Recent studies suggest that a population of cardiac stem cells (CSCs) is maintained after cardiac development in the adult heart in mammals including human beings; however, homeostatic cardiomyocyte replacement might be stem cell-dependent, and functional myocardial regeneration after cardiac muscle damage is not yet considered as sufficient to fully maintain or reconstitute the cardiovascular system and function. Although it is clear that adult CSCs have limitations in their capabilities to proliferate extensively and differentiate in response to injury in vivo for replenishing mature car-diomyocytes and potentially function as resident stem cells. Transplantation of CSCs expanded ex vivo seems to require an integrated strategy of cell growth-enhancing factor(s) and tissue engineering technologies to support the donor cell survival and subsequent proliferation and differentiation in the host microenvironment. There has been substantial interest regarding the evidence that mammalian fibroblasts can be genetically reprogrammed to induced pluripotent stem (iPS) cells, which closely resemble embryonic stem (ES) cell properties capable of differentiating into functional cardiomyocytes, and these cells may provide an alternative cell source for generating patient-specific CSCs for therapeutic applications.

KW - Cardiac stem cells

KW - Development

KW - Heart failure

KW - Reprogramming

UR - http://www.scopus.com/inward/record.url?scp=57149134526&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=57149134526&partnerID=8YFLogxK

U2 - 10.1111/j.1582-4934.2008.00487.x

DO - 10.1111/j.1582-4934.2008.00487.x

M3 - Article

VL - 12

SP - 2217

EP - 2232

JO - Journal of Cellular and Molecular Medicine

JF - Journal of Cellular and Molecular Medicine

SN - 1582-1838

IS - 6A

ER -